• LINC02870, SNAIL Translation, and HCC: Evidence Limits

  2026-10-13

  A source-grounded overview of a preprint linking LINC02870 with EIF4G1-associated SNAIL translation and hepatocellular carcinoma phenotypes, while distinguishing cellular and computational findings from clinical evidence. The article also clarifies the conceptual relevance—and limits—of Biotin-16-UTP without implying that the cited study used this reagent.

• LY-411575: Mechanism and Evidence Boundaries

  2026-10-13

  LY-411575 is described by APExBIO as a selective gamma-secretase inhibitor that affects both amyloid precursor protein processing and Notch signaling. The supplied peer-reviewed study by Satir et al. provides related evidence about partial beta-secretase inhibition and synaptic transmission, but it did not test LY-411575. The evidence therefore supports mechanistic research use and cautious pathway interpretation, not claims of clinical efficacy or compound-specific therapeutic benefit.

• RRP, Lipid Metabolism, and Liver Ischemia–Reperfusion

  2026-10-12

  A source-grounded overview of a Journal of Ethnopharmacology study reporting that Radix Rehmanniae Praeparata extracts reduced hepatic ischemia–reperfusion injury in mice and lipid-stress responses in hepatocytes, with proposed involvement of AMPK, SCAP–SREBP2, and LXRα pathways. The findings are mechanistic and preclinical, not evidence of clinical efficacy.

• STMN2 Loss Under Stress in ALS: An Editorial View

  2026-10-12

  The cited study argues that stress-related STMN2 depletion can occur through mechanisms beyond TDP-43 splicing failure. Its evidence links acute stress to protein loss through degradation, phosphorylation and translation repression, while chronic translation deficits may create a longer-term vulnerability in neuronal models. The findings are mechanistically informative but remain bounded by their cellular and animal-model provenance and do not establish a clinical treatment strategy.

• BRD4 Inhibition and Ferroptosis: Study Overview

  2026-10-11

  A source-grounded overview of a 2024 Discover Oncology study examining how BRD4 inhibition affects erastin-induced ferroptosis, with emphasis on reactive oxygen species, FSP1 regulation, evidence strength and limitations.

• Okadaic Acid Product Overview

  2026-10-09

  Okadaic acid (SKU A4540) is a marine-derived PP1 and PP2A inhibitor listed by APExBIO for conceptual research on phosphorylation-dependent signaling and apoptosis. No matched paper evidence is available here, so product performance and assay-specific applicability remain unvalidated.

• LY-411575: Reading Notch and Aβ Evidence Together

  2026-10-09

  LY-411575 is a potent gamma-secretase inhibitor for studying the shared biology of amyloid beta processing and Notch signaling. This article develops a causal framework linking biochemical potency to tumor-immune evidence while clarifying what the TNBC literature does—and does not—establish.

• Grazoprevir/Elbasvir: HCV Evidence Review

  2026-10-08

  The 2016 review by Vallet-Pichard and Pol explains the rationale for combining grazoprevir, an NS3/4A protease inhibitor, with elbasvir, an NS5A inhibitor, in interferon-free HCV therapy. Its evidence synthesis highlights high SVR rates, relevance to genotype 1 and 4 infection, and the importance of resistance, comorbidity, drug interactions, and changing treatment standards.

• SWI/SNF ATPases in H3.3K27M DIPG

  2026-10-07

  Mota and colleagues identified elevated SWI/SNF ATPase and PBAF-associated protein levels as a vulnerability in H3.3K27M diffuse intrinsic pontine glioma models. Their integrated genetic, pharmacologic, chromatin-accessibility, transcriptomic, and proteomic evidence links AU-15330-mediated degradation of SMARCA4, SMARCA2, and PBRM1 to reduced FOXO1-associated survival programs, while remaining limited to preclinical cellular systems.

• Antipyrine in BBB Permeability Research

  2026-10-07

  Antipyrine, also known as 1,5-dimethyl-2-phenylpyrazol-3-one, is a chemically defined analgesic and antipyretic research compound that may be relevant to pharmacokinetic studies and blood-brain barrier assessment. This overview examines its research context alongside a 2025 surrogate BBB model, separating published findings from interpretation and outlining limits on what the available evidence can support.

• Neomycin Sulfate: Mechanisms Across Biology

  2026-10-06

  Neomycin sulfate is an aminoglycoside antibiotic whose effects span RNA folding, DNA triplex stabilization, viral RNA–protein recognition, and ion-channel behavior. This article offers a cross-scale framework for interpreting those mechanisms alongside microbiome–immune research without confusing molecular probing with therapeutic evidence.

• Hydrocortisone in Biomedical Research: Evidence and Limits

  2026-10-06

  Hydrocortisone is an endogenous glucocorticoid hormone used as a reference compound for glucocorticoid receptor signaling, inflammation model research, and stress-response studies. Available evidence supports its value as a mechanistic probe, but the supplied prostate study concerns pleiotrophin rather than hydrocortisone, and commercial product descriptions should not be treated as equivalent to independently validated clinical or translational evidence.

• Solanesol Product Overview | APExBIO

  2026-10-05

  Solanesol is a supplier-described polyisoprenoid alcohol for research use. The available evidence is limited to product information, with no matched paper evidence provided to establish mechanisms, assay performance, or biological outcomes.

• EDI3 Inhibition in HER2-Therapy-Resistant Breast Cancer

  2026-10-05

  Keller et al. identify the glycerophosphodiesterase EDI3/GPCPD1 as a metabolically linked vulnerability in ER-HER2-positive breast cancer, including models resistant to HER2-targeted treatment. The study connects patient-tissue observations, signaling analysis, genetic perturbation, pharmacological inhibition, and tumor models, while supporting EDI3 as a preclinical target rather than an established clinical therapy.

• iPSC Cardiomyocytes for Chemical Hazard Prioritization

  2026-10-04

  Tsai and colleagues show that combining transcriptomic profiles with cardiomyocyte phenotypes can strengthen chemical hazard identification and risk characterization. Across 464 chemicals, the integrated framework connected functional effects, gene-expression changes, and exposure-informed points of departure while clarifying the limits of in vitro evidence.

8680 records 2/579 page Previous Next 12345 下5页 Last page